Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novartis is committed to improving access to its RLTs, Pluvicto and Lutathera ® (INN: lutetium (177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) by adding more treatment sites in closer ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration for commercial manufacturing of Pluvicto TM at its new large-scale, state ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility ...

New indication approximately triples eligible patient population, allowing Pluvicto ® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto ...